Clinical Trials Browser

Phase 3 × OTHER × Crizotinib × Clear all

NCT06254599 2024-02-12

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung